CTRI/2020/05/025067
Completed
未知
A randomized controlled trial of hydroxychloroquine prophylaxis for Healthcare Workers exposed to COVID-19
George Institute for Global Health India0 sites416 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- George Institute for Global Health India
- Enrollment
- 416
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •All HCWs directly exposed to confirmed COVID\-19 patients.
Exclusion Criteria
- •Participants who meet any of following criteria will be are excluded
- •1\. have a proven diagnosis of COVID\-19 infection
- •2\. are currently taking chloroquine or HCQ
- •3\. are pregnant
- •4\. are breast feeding
- •5\. known QT prolongation
- •6\. history of serious cardiac dysrhythmias or cardiomyopathy
- •7\. have maculopathy of the eye (a contra\-indication to HCQ)
- •8\. are immunocompromised because of a disease or therapy
- •9\. pregnant women
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Randomized controlled trial of hydroxychloroquine versus placebo in early ambulatory diagnosis and treatment of elderly COVID-19 PatientsCoronavirus diseaseTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-001482-37-DEniversity Hopsital Tuebingen350
Active, not recruiting
Phase 1
Systematic study of the medicine hydroxychloroquine against placebo for the treatment of adult patients with acute coronavirus disease 2019 – COVID-19Acute coronavirus disease 2019MedDRA version: 20.1Level: PTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 10021881 - Infections and infestationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-001224-33-DEniversitätsklinikum Tübingen220
Active, not recruiting
Phase 1
Trial of hydroxychloroquine in the treatment of adult patients with Covid-19 infection in a primary care settingCovid-19 infectionTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-002038-33-FIPorin kaupunki600
Active, not recruiting
Phase 3
Safety and Efficacy of Hydroxychloroquine Associated With Azythromycin in SARS-Cov-2 VirusRBR-9d8z6mHospital do Coração
Active, not recruiting
Phase 1
PROTECT: studio randomizzato con idrossiclorochina vs osservazione per la prevenzione e il trattamento precoce della malattia da coronavirus (COVID-19)Group 1: SARS-CoV-2-exposed subjects, as household members/contacts of COVID-19 patientsGroup 2: Patients with COVID-19 asymptomatic or paucisymptomatic in home situationMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862Therapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-001501-24-ITISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI (IRST) S.R.L. IRCCS2,300